GMO Financial Gate, Inc. Beat Revenue Forecasts By 9.0%: Here's What Analysts Are Forecasting Next
Last week saw the newest third-quarter earnings release from GMO Financial Gate, Inc. (TSE:4051), an important milestone in the company's journey to build a stronger business. Results overall were respectable, with statutory earnings of JP¥54.85 per share roughly in line with what the analysts had forecast. Revenues of JP¥5.7b came in 9.0% ahead of analyst predictions. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
After the latest results, the five analysts covering GMO Financial Gate are now predicting revenues of JP¥23.2b in 2027. If met, this would reflect a notable 11% improvement in revenue compared to the last 12 months. Per-share earnings are expected to bounce 35% to JP¥291. Yet prior to the latest earnings, the analysts had been anticipated revenues of JP¥23.1b and earnings per share (EPS) of JP¥290 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.
Check out our latest analysis for GMO Financial Gate
It will come as no surprise then, to learn that the consensus price target is largely unchanged at JP¥9,125. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on GMO Financial Gate, with the most bullish analyst valuing it at JP¥9,900 and the most bearish at JP¥8,350 per share. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's pretty clear that there is an expectation that GMO Financial Gate's revenue growth will slow down substantially, with revenues to the end of 2027 expected to display 8.6% growth on an annualised basis. This is compared to a historical growth rate of 20% over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue shrink 0.7% per year. So it's clear that despite the slowdown in growth, GMO Financial Gate is still expected to grow meaningfully faster than the wider industry.
The Bottom Line
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, they also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Their estimates also suggest that GMO Financial Gate's revenue is expected to perform better than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple GMO Financial Gate analysts - going out to 2028, and you can see them free on our platform here.
You should always think about risks though. Case in point, we've spotted 2 warning signs for GMO Financial Gate you should be aware of, and 1 of them shouldn't be ignored.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.